Lumida
/ARWR
⌘K
Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

ARWR
$74.30USD↑+4.10%+2.92 today

MARKET CAP

10.5B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$70 – $75

52W RANGE

$14
$88

AI Summary

Stalk
StalkMedium

ARWR remains in a Stage 2 advancing regime with clear higher highs and higher lows supported by rising EMAs and volume expansion—preserving a bullish medium-term outlook. However, the recent Bullish Exhaustion candle, price extension above key EMAs, and RSI nearing overbought levels signal short-term fatigue. We will Stalk for a corrective pullback into the 9/21 EMA zone for a potential entry.

  • ↑Redempla FDA-approved for FCS generates 400+ prescriptions post-launch
  • ↑FY25 revenue surged to $829 M, cash balance $919 M supports R&D
  • ↓Q2 operating expenses climbed to $731 M, accelerating cash burn
Full analysis →
Insider Trades39 trades
Date↓SideTicker↕Insider↕Role↕Shares↕Price↕Mkt Cap↕52W High↕52W Low↕Value↕% Chg↕Rule↕AI View↕
Apr 23, 2026SellARWRJames C HamiltonChief Medical Officer10,000$75.00$10.5B-15.40%+419.58%$750.0K-4.22%10b5-1Stalk
Apr 22, 2026SellARWRDaniel Joseph ApelChief Financial Officer13,095$71.35$10.5B-15.40%+419.58%$934.3K-2.52%10b5-1Stalk
Mar 5, 2026SellARWRJames C HamiltonChief Medical Officer10,000$64.19$10.5B-15.40%+419.58%$641.9K-4.05%10b5-1Stalk
Jan 6, 2026SellARWRPatrick O'BrienCOO2,500$70.81$10.5B-15.40%+419.58%$177.0K-0.11%—Stalk
Jan 5, 2026SellARWRJames C HamiltonChief Medical Officer40,164$63.11$10.5B-15.40%+419.58%$2.5M-3.03%10b5-1Stalk
Jan 2, 2026SellARWRChristopher Richard AnzaloneChief Executive Officer13,187$66.10$10.5B-15.40%+419.58%$871.7K-0.17%10b5-1Stalk
Dec 31, 2025SellARWRPatrick O'BrienCOO52,293$59.73$10.5B-15.40%+419.58%$3.1M-0.61%10b5-1Stalk
Dec 29, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer103,452$37.64$10.5B-15.40%+419.58%$3.9M+0.00%10b5-1Stalk
Dec 19, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer26,031$68.04$10.5B-15.40%+419.58%$1.8M-0.14%—Stalk
Dec 17, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer85,000$64.04$10.5B-15.40%+419.58%$5.4M-0.55%—Stalk
Dec 15, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer184,298$67.00$10.5B-15.40%+419.58%$12.3M-0.39%—Stalk
Oct 1, 2025SellARWRJames C HamiltonChief Medical Officer20,000$35.00$10.5B-15.40%+419.58%$700.0K-8.62%10b5-1Stalk
Sep 12, 2025SellARWRJames C HamiltonChief Medical Officer15,000$30.00$10.5B-15.40%+419.58%$450.0K-6.07%10b5-1Stalk
Sep 2, 2025SellARWRJames C HamiltonChief Medical Officer15,000$25.00$10.5B-15.40%+419.58%$375.0K-5.72%10b5-1Stalk
Aug 13, 2025SellARWRJames C HamiltonChief Medical Officer10,000$20.00$10.5B-15.40%+419.58%$200.0K-1.84%10b5-1Stalk
Apr 9, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer141,122$10.87$10.5B-15.40%+419.58%$1.5M-0.70%—Stalk
Mar 13, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer51,425$15.07$10.5B-15.40%+419.58%$775.0K-1.25%—Stalk
Mar 3, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer600,000$12.67$10.5B-15.40%+419.58%$7.6M+0.00%10b5-1Stalk
Feb 7, 2025BuyARWRChristopher Richard AnzaloneChief Executive Officer9,550$20.10$10.5B-15.40%+419.58%$192.0K+0.25%—Stalk
Jan 6, 2025SellARWRJames C HamiltonChief Discovery/Trans Medicine32,729$19.82$10.5B-15.40%+419.58%$648.8K-5.57%10b5-1Stalk
Jan 6, 2025SellARWRPatrick O'BrienCOO and General Counsel37,184$19.80$10.5B-15.40%+419.58%$736.1K-2.26%10b5-1Stalk
Jan 6, 2025SellARWRKenneth Allen MyszkowskiChief Financial Officer45,167$19.77$10.5B-15.40%+419.58%$893.1K-2.35%10b5-1Stalk
Jan 2, 2025SellARWRChristopher Richard AnzaloneChief Executive Officer11,520$19.05$10.5B-15.40%+419.58%$219.5K-0.31%10b5-1Stalk
Dec 23, 2024SellARWRChristopher Richard AnzaloneChief Executive Officer12,563$19.59$10.5B-15.40%+419.58%$246.1K-0.33%10b5-1Stalk
Dec 18, 2024SellARWRChristopher Richard AnzaloneChief Executive Officer26,712$21.24$10.5B-15.40%+419.58%$567.5K-0.24%10b5-1Stalk
Jul 2, 2024SellARWRTracie OliverChief Commercial Officer9,394$25.28$10.5B-15.40%+419.58%$237.5K-6.88%10b5-1Stalk
Apr 1, 2024SellARWRJames C HamiltonChief Discovery/Trans Medicine6,000$28.03$10.5B-15.40%+419.58%$168.2K-2.85%—Stalk
Mar 6, 2024SellARWRKenneth Allen MyszkowskiChief Financial Officer40,000$35.19$10.5B-15.40%+419.58%$1.4M-9.08%—Stalk
Jan 31, 2024SellARWRChristopher Richard AnzaloneChief Executive Officer114,998$23.44$10.5B-15.40%+419.58%$2.7M+0.00%10b5-1Stalk
Jan 12, 2024SellARWRJames C HamiltonChief Discovery/Trans Medicine7,940$36.89$10.5B-15.40%+419.58%$292.9K-1.83%10b5-1Stalk
Jan 5, 2024SellARWRTracie OliverChief Commercial Officer74$33.89$10.5B-15.40%+419.58%$2.5K-0.05%10b5-1Stalk
Jan 5, 2024SellARWRMartin Javier SanChief Medical Officer8,303$35.26$10.5B-15.40%+419.58%$292.8K-1.35%10b5-1Stalk
Jan 5, 2024SellARWRKenneth Allen MyszkowskiChief Financial Officer16,104$35.27$10.5B-15.40%+419.58%$567.9K-1.18%10b5-1Stalk
Jan 3, 2024SellARWRPatrick O'BrienCOO and General Counsel33,190$34.36$10.5B-15.40%+419.58%$1.1M-0.95%10b5-1Stalk
Jan 2, 2024SellARWRChristopher Richard AnzaloneChief Executive Officer9,952$31.01$10.5B-15.40%+419.58%$308.6K-0.13%10b5-1Stalk
Dec 20, 2023SellARWRChristopher Richard AnzaloneChief Executive Officer12,000$28.54$10.5B-15.40%+419.58%$342.5K-0.32%10b5-1Stalk
Nov 20, 2023SellARWRMartin Javier SanChief Medical Officer19,700$28.80$10.5B-15.40%+419.58%$567.3K-6.83%—Stalk
Oct 25, 2023SellARWRChristopher Richard AnzaloneChief Executive Officer24,338$24.21$10.5B-15.40%+419.58%$589.2K-0.65%10b5-1Stalk
Sep 18, 2023SellARWRChristopher Richard AnzaloneChief Executive Officer115,510$16.44$10.5B-15.40%+419.58%$1.9M+0.00%10b5-1Stalk